Navigation Links
Alexza Pharmaceuticals Provides Regulatory Update for AZ-004 (Staccato® Loxapine)
Date:12/7/2010

is a pharmaceutical company focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions. Alexza's technology, the Staccato® system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience. (Click here to see an animation of how the Staccato system works.)

AZ-004 (Staccato loxapine) is Alexza's lead program, which is being developed for the rapid treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials and submitted the AZ-004 NDA in December 2009.  In October 2010, the Company received a CRL from the FDA, regarding its NDA for AZ-004.  A CRL is issued by FDA's Center for Drug Evaluation and Research indicating that the NDA review cycle is complete and the application is not ready for approval in its present form.  The Company is currently evaluating the FDA's comments in the CRL and has scheduled a meeting with the FDA in December 2010 to discuss the CRL.

For more information about Alexza, the Staccato technology or the Company's development programs, please visit www.alexza.com.

Safe Harbor Statement

This press release includes forward-looking statements regarding the development and safety of the Company's product candidates and technologies.  Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Se
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... BURLINGTON, Mass. , July 31, 2014 ... healthcare funding changes brought about by the ... both reimbursement and prescribing of pharmaceutical therapies. ... (MCOs) cover beneficiaries through new regulations and ... is occurring in the health exchanges—state-based marketplaces ...
(Date:7/31/2014)... Touro University California,s College of Pharmacy is ... recipient of a $150,000 grant by the Joseph & ... increase research and classroom space on its campus. ... study of health sciences, and will help us apply ... of our students," said Shelley Berkley , CEO ...
(Date:7/31/2014)... -- For its innovative modular Biomedical Research building in ... has earned a Modular Building Institute (MBI) 2014 Award ... categories, MBI,s contest is the commercial modular industry,s premier ... dealers, and product and service providers. ... our team," said Dan Palmer , President of ...
Breaking Medicine Technology:Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 2Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 4Touro University California Garners Grant From Long Foundation 2Art's Way Scientific Earns Prestigious Modular Building Institute Award 2Art's Way Scientific Earns Prestigious Modular Building Institute Award 3Art's Way Scientific Earns Prestigious Modular Building Institute Award 4
... Data presented today,at the Annual Congress of ... oral Factor Xa inhibitor DU-176b reduced the incidence,of ... elective unilateral hip replacement surgery. There was a,statistically ... the,observed bleeding rates were low across the groups. ...
... Bypass Surgery for Safety and ... Condition, WASHINGTON, Sept. 1 Patients with both ... will find good news in,new findings announced today from ... Interventions (SCAI). The one-year findings,of the new study indicate ...
Cached Medicine Technology:Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b 2SCAI: CARDia Data Find Diabetic Patients With Complex Heart Disease Can Safely Choose PCI 2SCAI: CARDia Data Find Diabetic Patients With Complex Heart Disease Can Safely Choose PCI 3
(Date:8/1/2014)... 01, 2014 The European gas chromatography systems ... analysis and forecast of revenue. The gas chromatography systems market ... is estimated to grow to around $247.6 million by 2018, ... Browse through the TOC of the European gas chromatography systems ... This also provides a glimpse of the segmentation of gas ...
(Date:8/1/2014)... According to a new market research report of ... Types, Applications (Automotive, Petrochemical, Consumer Utility, Glass, and Aerospace ... - Analysis & Forecast to 2010 - 2020", published ... to $1.42 Billion by 2020 at a CAGR of ... grow to $238.17 Million by 2020 at a CAGR ...
(Date:8/1/2014)... Society of America (GSA) the nation,s ... aging has chosen J. Jill Suitor, PhD, ... the Distinguished Career Contribution to Gerontology Award. , ... individual whose theoretical contributions have helped bring about ... original and elegant research designs addressing a significant ...
(Date:8/1/2014)... of America (GSA) the nation,s largest ... has chosen Madonna Harrington Meyer, PhD, of ... University of Luxembourg; and Philipp Hessel, MA, MSc, ... of Economics and Political Science as the 2014 ... , These distinguished honors recognize insightful and innovative ...
(Date:8/1/2014)... August 01, 2014 Lifeinsurancenomedicalexam.info has ... life insurance for clients who have high cholesterol levels. ... still find and qualify for no medical exam life ... requiring any background medical check-ups. , Since there are ... cholesterol level will qualify in just a few minutes. ...
Breaking Medicine News(10 mins):Health News:European Gas Chromatography (GC) Systems Market is Expected to Reach $247.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:European Gas Chromatography (GC) Systems Market is Expected to Reach $247.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:European Gas Chromatography (GC) Systems Market is Expected to Reach $247.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Thermocouples Market worth $1.42 Billion & High End Optical Pyrometers Market worth $ 238.17 Million by 2020 2Health News:Thermocouples Market worth $1.42 Billion & High End Optical Pyrometers Market worth $ 238.17 Million by 2020 3Health News:Thermocouples Market worth $1.42 Billion & High End Optical Pyrometers Market worth $ 238.17 Million by 2020 4Health News:Suitor to receive GSA's 2014 Distinguished Career Contribution to Gerontology Award 2Health News:Harrington Meyer, Leist, Hessel, Avendano to receive GSA's 2014 Kalish awards 2Health News:No Exam Life Insurance - Coverage for Clients Who Have High Cholesterol 2
... ... educational stories, NEW YORK, May 12 ... Gamble Pharmaceuticals (P&G), has,selected seven winners for the Celebrating UC Success ... by ulcerative,colitis. Winners, stories reflect a wide variety of experiences with,ulcerative ...
... 12 FutureScripts(R), the premier,pharmacy benefit manager in ... . The website is a valuable tool for ... find key,information about the drugs on FutureScripts, formulary, ... "The new website allows our customers to find ...
... in French . , Montreal, May 12, 2008 ... in some cases, emotional and physical pain can linger for ... Universit de Montral graduate student Emma Duerden is inviting amputees ... study. , Our main goal is to better understand why ...
... homeless youth suggests that treating substance abuse and mental health ... the streets. , Instead, researchers found that creating more opportunities ... factors in reducing homelessness. , A study of 180 ... most social stability, such as those who attended school more ...
... is Disability Insurance Awareness Month; LIFE Foundation Reviews Common, Misconceptions to Encourage ... ... Needs, ARLINGTON, Va., May 12 If you were ... yourself,financially? The results of a new survey released today by the nonprofit,LIFE ...
... uncover ... system abuse, HORSEHEADS, N.Y., May ... in 2007. With so many recipients and,providers involved, the New York State ... abuse., Over the last two years, Salient Corporation, provider of the ...
Cached Medicine News:Health News:UPDATE: Celebrating UC Success Announces Essay Contest Winners 2Health News:UPDATE: Celebrating UC Success Announces Essay Contest Winners 3Health News:UPDATE: Celebrating UC Success Announces Essay Contest Winners 4Health News:UPDATE: Celebrating UC Success Announces Essay Contest Winners 5Health News:UPDATE: Celebrating UC Success Announces Essay Contest Winners 6Health News:Pharmacy Benefit Manager FutureScripts(R) Launches New Website 2Health News:Pharmacy Benefit Manager FutureScripts(R) Launches New Website 3Health News:Homeless youth need more than treatment for substance abuse, study says 2Health News:Homeless youth need more than treatment for substance abuse, study says 3Health News:New Survey Finds Overwhelming Majority of Working Americans Not Financially Prepared for Disability, Would Rely on Sources Other than Themselves for Support 2Health News:New Survey Finds Overwhelming Majority of Working Americans Not Financially Prepared for Disability, Would Rely on Sources Other than Themselves for Support 3Health News:New Survey Finds Overwhelming Majority of Working Americans Not Financially Prepared for Disability, Would Rely on Sources Other than Themselves for Support 4Health News:Salient Corporation's Performance Management Solution Helps NY State Counties Identify Medicaid Fraud, Waste, and Abuse 2
... designed to validate HDL cholesterol plus other ... This control is compatible with most major ... Synchron and Vitros. HDL values are given ... methods: Dextran Sulfate 50,000 MW. Apolipoprotein A-1 ...
... is intended as a means ... ethanol assay methods. This ready-to-use, ... clinically significant levels of ammonia ... provided for the following instruments: ...
... This unassayed control is intended ... manual and automated assay methods ... oxalate in human urine samples. ... requiring no reconstitution. This control ...
... Microbumin is a two-level control ... Clinitek Microalbumin Reagent Strips and Roche ... also suitable for turbidimetric immunoassays using ... and DCA 2000, Cobas, Diasorin SPQ ...
Medicine Products: